Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages

Abstract We provide updated results (11 October 2023 through 29 February 2024) from our previously conducted test-negative case-control study in Kaiser Permanente Southern California to evaluate sublineage-specific effectiveness of the BNT162b2 XBB1.5-adapted vaccine. Results suggest that XBB1.5-ada...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Open Forum Infectious Diseases 2024-07, Vol.11 (7), p.ofae370
Hauptverfasser:	Tartof, Sara Y, Slezak, Jeff M, Puzniak, Laura, Frankland, Timothy B, Ackerson, Bradley K, Jodar, Luis, McLaughlin, John M
Format:	Artikel
Sprache:	eng
Schlagworte:	Coronaviruses Health aspects Health maintenance organizations Pharmaceutical industry Severe acute respiratory syndrome Vaccines Vaccines and Immunization
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract We provide updated results (11 October 2023 through 29 February 2024) from our previously conducted test-negative case-control study in Kaiser Permanente Southern California to evaluate sublineage-specific effectiveness of the BNT162b2 XBB1.5-adapted vaccine. Results suggest that XBB1.5-adapted vaccines may have reduced effectiveness against JN.1 versus XBB sublineages.
ISSN:	2328-8957 2328-8957
DOI:	10.1093/ofid/ofae370